Polycomb proteins in hematologic malignancies

56Citations
Citations of this article
82Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The Polycomb group (PcG) of proteins is a major mechanism of epigenetic regulation that has been broadly linked to cancer. This system can repress gene expression by chromatin modification and is essential for establishing cell identity. PcG proteins are important for stem cell function and differentiation and have a profound impact during hematopoiesis. In recent years, several published studies have deepened our knowledge of the biology of the PcG in health and disease. In this article, we review the current understanding of the mechanisms of PcG-mediated repression and their relation to DNA methylation, and we discuss the role of the PcG system in hematopoiesis and hematologic malignancies. We suggest that alteration of different PcG members is a frequent event in leukemia and lymphomas that confers the stem cell properties on tumor cells. Thus, drugs targeting Polycomb complexes could be useful for treating patients with these diseases. © 2010 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Martin-Perez, D., Piris, M. A., & Sanchez-Beato, M. (2010, December 16). Polycomb proteins in hematologic malignancies. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2010-05-267096

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free